About US
Contact us
-
AstraZeneca, Pfizer, Novartis and more lose out in China's latest round of drug price cutsIn another abysmal day for large pharma companies’ off-patent drugs, generics makers have once again offered hefty discounts to win large tender offers in China, elbowing out original developers.2022/8/18
-
Pfizer partner CStone explores sale as US path blocked, Chinese competition heats up: BloombergA Pfizer cancer drug partner in China is considering a sale as the biotech’s commercial path in the U.S. looks uncertain and competition in its home country intensifies. CStone Pharmaceut2022/8/18
-
AstraZeneca, Pfizer, Novartis and more lose out in China's latest round of drug price cutsIn another abysmal day for large pharma companies’ off-patent drugs, generics makers have once again offered hefty discounts to win large tender offers in China, elbowing out original developers.2022/8/16
-
Pfizer partner CStone explores sale as US path blocked, Chinese competition heats up: BloombergA Pfizer cancer drug partner in China is considering a sale as the biotech’s commercial path in the U.S. looks uncertain and competition in its home country intensifies. CStone Pharmaceut2022/8/16
-
WuXi unveils new production capabilities at Changzhou campus amid expansion pushWuXi STA, a part of WuXi AppTec,unveilednew large-scale oligonucleotide and peptide manufacturing capabilities at its Changzhou production campus. The 30,570-square-foot oligonucleotide f2022/8/11
-
BeiGene R&D chief's I-O ambitions; Legend scraps CAR-T programBeiGene's R&D chief talked to Fierce Biotech about the company's PD-1 plans and how its TIGITplans are still alive despite Roche's recent trial failures. Expanding on novel technologies, BeiGenea2022/8/11
-
Athenex unloads stake in Chinese API production business for $19M to bolster its financialsStruggling biotech Athenexunloadedall of its equity interests in its Chinese subsidiaries that produce APIs as part of a $19 million deal with TiHe Capital of Beijing. Under terms of the2022/8/9
-
AstraZeneca, Pfizer, Novartis and more lose out in China's latest round of drug price cutsIn another abysmal day for large pharma companies’ off-patent drugs, generics makers have once again offered hefty discounts to win large tender offers in China, elbowing out original developers.2022/8/9
-
Eying Pfizer, Alnylam's high-stakes Onpattro heart trial delivers partial win but misses on key outcomes goalAfter an investigational BridgeBio drug surprisingly failed a clinical trial that would have set up a fight against Pfizer in a rare heart condition, investors have been worrying about Alnylam becaus2022/8/4
-
Teva runs into Adderall supply hitch as ADHD diagnoses mount, pledges prompt restockingAmid a national spike in attention-deficit/hyperactivity disorder diagnoses, one of the U.S.’ top providers of a popular ADHD medication has run into supply problems. Both 20-mg and 30-mg2022/8/4